Moxalactam treatment of serious infections primarily due to Haemophilus influenzae type b in children.

Thirty-eight children completed therapy with moxalactam for a variety of non-CNS infections. Haemophilus influenzae type b (seven ampicillin-resistant strains) was the etiologic agent for 32 children. Doses of moxalactam ranged from 113 to 200 mg/kg/d in three or four divided doses administered parenterally.

Pharmacology and cerebrospinal fluid penetration of moxalactam in children and dosage recommendations.

The pharmacokinetics and penetration into cerebrospinal fluid (CSF) of moxalactam were evaluated in 20 children with bacterial meningitis. After moxalactam was given iv as a loading dose of 100 mg/kg followed by two doses of 50 mg/kg every 6 hr, the mean serum concentrations were 205 micrograms/ml at the end of the last infusion and 11 micrograms/ml at 6 hr. The beta elimination half-life was 3.

Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience.

Over a 3-year period, 96% of systemic infections in children caused by Haemophilus influenzae were of serotype b. Of 346 invasive infections, 15 (4%) were caused by non-type b H. influenzae.

Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.

The serum pharmacokinetics and CSF penetration of moxalactam were determined in 39 children with bacterial meningitis. The mean serum concentrations 30 minutes after a 37.5 or 50 mg/kg dose were 66.